Hersh Chandarana1, Ely Felker1, Bachir Taouli1,2
1Radiology, NYU Langone Medical Center, New York, NY, United States; 2Radiology, Mount Sinai Medical Center, New York, NY, United States
Gd-EOB-DTPA is recently FDA approved liver-specific contrast agent which has shown potential in liver lesion detection and characterization when delayed (~ 20 min.) post-contrast imaging is performed. However, extending imaging protocol by 20 minutes is not convenient. One approach to decrease imaging time is to perform T2 (T2WI) and diffusion imaging (DWI) after contrast injection between equilibrium and delayed phases of enhancement. In this study, we evaluated effect of Gd-EOB-DTPA on liver and lesion signal intensity on T2WI and DWI and demonstrated minimal effect on liver T2 SI, and no significant change on liver and lesion apparent diffusion coefficient (ADC).